SGLT2 inhibitors did not show any significant effect on the incidence of amputation (RR 1.12; 95% CI: 0.97–1.30; p for heterogeneity 0.63; I2 = 0%; p = 0.12), bone fracture (RR 1.04; 95% CI: 0.96–1.13; p for heterogeneity 0.83; I2 = 0%; p = 0.36), hypoglycemia (RR 0.96; 95% CI: 0.92–1.01; p for heterogeneity 0.18; I2 = 31%; p = 0.17), thromboembolic events (RR 0.83; 95% CI: 0.59–1.17; p for heterogeneity 0.82; I2 = 0%; p = 0.28), or urinary tract infection (RR 1.05; 95% CI: 0.99–1.12; p for heterogeneity 0.24; I2 = 27%; p = 0.09) (Supplementary Figure 2). This evidence concerns the gene SLC5A2 and urinary tract infection.